Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Steve's Channelling Thread -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (7911)	11/16/2000 1:27:09 PM
From: Zeev Hed	Read Replies (1) \| Respond to of 30051

Casaubon, it is true, the reason is that psoriasis is highly a stress related syndrome and furthermore, not uniform in its etiology. As a result, the placebo effect is very high, 25%. Most drugs show a $25% to 30% efficacy, not sufficient to pass the comparison with placebo. However, I have reasons to believe that photodynamic approaches will be more successful. First these are already applied (both direct UV and psoralen in conjunction with UV) successfully. By moving the radiation spectrum outside of the "DNA damaging" part of the spectrum, they have a good chance of coming up with something better. By the way, the SOX just printed a new low for the day, so I decided to take the bu$$ off the table, I got $61-11/16, just a 1/16 above my buy. I also bailed out of SCMR at $66.5, BRCD at $229 (a small gain) CREE at $107.5, a small loss and ARBA at $84.75 (another loss on this one today). I am staying with BRCD for the time being, but if it gets under $148, it is out as well. Zeev In edit, I forgot to mention VTSS it went at a minimal lossat $68-5/8. You win some and lose some, this morning was win day and this afternoon is lose day.